HER2 Vaccine for Locally Advanced Breast Cancer
The goal of this study is to test an investigational vaccine to activate the immune system to fight breast cancer.
Trial Details
- NCT ID
- NCT06949410
- Phase
- PHASE1
- Sponsor
- Pravin T.P Kaumaya
- Status
- RECRUITING
- Cancer Type
- HER2 Positive Breast Cancer
- Interventions
- Locations (sample)
- Indianapolis, Indiana, United States|39.76838,-86.15804
Key Eligibility Criteria
- ≥ 18 years old at the time of informed consent
- Ability to provide written informed consent and HIPAA authorization CTO-IUSCC-0864
- Histologically confirmed HER2 positive breast cancer
- Any Estrogen Receptor/Progesterone Receptor status is allowed.
For full eligibility, visit ClinicalTrials.gov.